Research

Researchers Develop Marburg Virus Treatment Effective Five Days After Infection

Virus causes hemorrhagic fever often leading to death


By Donna Ramirez | April 07, 2017

An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical Inc., and Vanderbilt University. The findings are now available in Science Translational Medicine.

There are currently no vaccines or drugs approved for human use to protect against the Marburg and Ravn viruses. These two filoviruses, which are in the same virus family as Ebola, cause severe and often lethal disease in people. The average case fatality rate of Marburg virus disease since the first recognized outbreak in 1967 is 80 percent.

Monoclonal antibodies are a technology that is currently in wide use for treating autoimmune diseases and cancers. There are more than 45 monoclonal antibodies approved by the U.S. Food and Drug Administration and European Medicines Agency.

“In this paper, we demonstrated that one monoclonal antibody is able to protect up to 100 percent of Marburg or Ravn virus-infected non-human primates when the antibody treatment is given up to five days following exposure to a lethal amount of the virus,” said UTMB’s Thomas Geisbert, professor in the department of microbiology and immunology. “These findings extend the growing body of evidence that monoclonal antibodies can provide protection during advanced stages of disease with highly dangerous viruses and could be useful during an epidemic.”

The study was conducted in Biosafety Level (BSL)-4 at UTMB’s Galveston National Laboratory. BSL-4 is a highly-restricted area where scientists wear positive pressure protective suits and study pathogens that cause severe and often fatal diseases. UTMB has the only functioning BSL-4 laboratory located on an American university campus.

The 2013 to 2016 Ebola virus epidemic highlighted the troubling lack of preventive or treatment options for filoviruses. Some of the therapeutics used to treat those infected with Ebola were developed and tested in the GNL.

“The level of protection observed by Dr. Geisbert’s team with this antibody is very impressive. We plan to advance this product towards human safety testing as quickly as possible,” said Larry Zeitlin, president of Mapp Biopharmaceutical Inc.

Other authors of this paper include UTMB’s Chad Mire, Joan Geisbert, Viktoriya Borisevich, Karla Fenton, Krystle Agans and Daniel Deer; Andrew Flyak and James Crowe, Jr. from Vanderbilt University Medical Center; Herta Steinkellner from the University of Natural Resources and Life Sciences in Vienna and Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do Kim, Michael Pauly, Jesus Velasco and Kevin Whaley.

This study was supported by the Department of Health and Human Services, National Institutes of Health and BSL-4 operations support of the Galveston National Laboratory.

Tags | Research



Social Posts

profile_image

Houston Methodist

@MethodistHosp

@lgreenspoon07 We can't directly treat medical issues online. Please call our Health Information Line at 713.790.33… https://t.co/5Yd3sCjze4

5 hours ago
profile_image

Houston Methodist

@MethodistHosp

@HPMNews887 Thanks for sharing the info ^SF

5 hours ago
profile_image

Houston Methodist

@MethodistHosp

@nejmcatalyst Thanks for the shout-out ^SF

5 hours ago

Lalita Singh Datla

Lalita Singh Datla

Does anyone know if the buses from victory lakes park and ride to Utmb be operating tomorrow?

5 hours ago
profile_image

Houston Methodist

houstonmethodist

From miso soup to sauerkraut, these probiotic foods provide benefits to your gut & your immune system.

5 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

.@theNASciences has recognized our Dr. Jim Allison for his pioneering work in #immunotherapy by honoring him with t… https://t.co/T8KnBYhaaS

6 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

RT @DrVictorHassid: Super proud of all 5 @MDAndersonNews campuses.Regardless of challenges we show again and again how committed we are to…

6 hours ago
profile_image

BCMHouston

@bcmhouston

Snow, and ice, and sensitive skin, oh my! Make sure you're using the right skincare products to protect your skin!… https://t.co/8sBSb5bKZG

7 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

Ceremony honors Veterans of Operation Desert Storm https://t.co/wPfjPdZ2nc via @Channel8ABC

7 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

Awesome job on P7! Thanks for taking great care of our patients. https://t.co/HWpKNlnF7f

8 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

Native American Veterans will be honored with memorial on National Mall https://t.co/aUeQnfDReU via @denverpost

8 hours ago
profile_image

Rice University

RiceUniversity

Rice University will be open for normal business and classes on Thursday, Jan. 18.

8 hours ago
profile_image

Rice University

@RiceUniversity

Rice University will be open for normal business and classes on Thursday, Jan. 18.

8 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

Today's #VeteranOfTheDay is @USArmy Veteran Wilbur Red Elk Ellis https://t.co/iDnNIwHwhN #VietnamVet

9 hours ago
profile_image

BCMHouston

@bcmhouston

RT @METROHouston: THURSDAY: We're planning on a regular day of service. Please expect some delays and possible detours, though. FULL DETAIL…

9 hours ago